Steroid Use in Non-RSV Bronchiolitis

Dexamethasone Use for the Treatment of Non-RSV Bronchiolitis

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04221087

Enrollment

Registered

2020-01-09

Start date

2020-02-03

Completion date

2022-12-31

Last updated

2023-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis, Viral

Keywords

bronchiolitis, non-RSV bronchiolitis, dexamethasone, treatment, steroid

Brief summary

The proposed study is a pilot randomized control trial to determine the efficacy of dexamethasone use in hospitalized children who are less than 2 years of age with non-respiratory syncytial virus (RSV) bronchiolitis admitted to the University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh from February 1 to May 31, 2022. It is hypothesized that the use of standard airway-dose steroids (0.6mg/kg dexamethasone) will improve the clinical outcome of children hospitalized for non-RSV bronchiolitis, which will be evident by decreased length of stay.

Detailed description

The study will take place at UPMC Children's Hospital of Pittsburgh with patients admitted to the general pediatric service. The attending physician on the clinical service team will identify patients diagnosed with bronchiolitis. If the participant meets inclusion and exclusion criteria, a member from the study team will then meet with the participant's family to discuss the study and obtained informed consent. A participant may have had a rapid RSV/influenza testing already complete for clinical purposes. If this has been done, participants will be asked to obtain a secondary nasopharyngeal swab so that it may be tested for a full respiratory viral panel for statistical stratification. Once rapid testing is obtained and results are negative for both RSV and influenza, the participant will then be randomized to either the intervention (dexamethasone) or control (placebo) arm of the study. Study members will calculate a modified Tal score (MTS) at time of consent and then 12-24 hours after medication administration. Throughout admission, participants will also receive standard of care for bronchiolitis, which may include regular vital sign evaluation, supplemental oxygen, intravenous fluids or nasogastric tube feedings, and anti-pyretic therapy. Because this is a pilot study, the study will be underpowered, however, this study will provide data that will allow the investigators to estimate the sample size needed for a future study. The number of time points to be used for the generalized estimating equation can be determined ad hoc to include a reasonably balanced sample to make the comparison valid.

Interventions

DRUGPlacebos

Sugar water based on same ml dosing of intervention arm drug

DRUGDexamethasone Oral

0.6mg/kg/dose - single oral dose administration to intervention arm

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Participants will be randomized to either intervention or control group upon admission if they meet inclusion/exclusion criteria and consent.

Eligibility

Sex/Gender

ALL

Age

1 Days to 2 Years

Healthy volunteers

Inclusion criteria

1. Less than or equal to 24 months 2. First episode of wheezing or first clinical diagnosis of bronchiolitis 3. Admitted to the general pediatric service at UPMC Children's Hospital of Pittsburgh 4. Ability of a parent or guardian to understand and comply with the study procedures 5. Signed written informed consent by parent or guardian

Exclusion criteria

1. Preterm birth \< 35 weeks 2. Presence of underlying cardiopulmonary, neuromuscular, or other complex disease 3. Admission to the pediatric intensive care unit 4. Co-infection with influenza infection or concomitant bacterial infection (such as pneumonia or AOM) 5. History of allergy or reaction to steroids 6. History of an underlying chronic medical condition -including chronic heart disease, chronic lung disease (except asthma),congenital anomalies of the airways or lung, cystic fibrosis, chronic renal disease including nephrotic syndrome, protein losing enteropathy of any cause, severe malnutrition, neurocognitive disorders, metabolic disorders (including phenylketonuria), or genetic disorders (note: genetic syndromes such as Down syndrome and Edwards Syndrome are excluded; however, children with genetic disorders (e.g., hemophilia) but who do not have a genetic syndrome may not satisfy this particular exclusion criterion; it is important that children with such genetic disorders do not have symptoms and/or comorbidities that would pose additional risk to them nor jeopardize the adequacy of study assessments.) 7. History of a condition that compromises the immune system - human immunodeficiency virus infection, primary immunodeficiency, anatomic or functional asplenia; receipt of a hematopoietic stem cell or solid organ transplant at any time; receipt of immunosuppressive therapy including chemotherapeutic agents, biologic agents, antimetabolites or radiation therapy during the past 12 months; or daily use of systemic corticosteroids for more than 7 consecutive days during the past 14 days. 8. Any other condition that in the judgment of the investigator precludes participation because it could affect the safety of the subject

Design outcomes

Primary

Measure	Time frame	Description
Hospital Length of Stay	Admission vitals through discharge paperwork printing time, average of 24-96 hours	Measurement of hospital length of stay in hours

Secondary

Measure	Time frame	Description
Severity of Bronchiolitis	Will obtain MTS upon admission by chart view or, if unable, at time of enrollment, and compare to MTS obtained 12 hours after medication administration	Measurement of reducing severity of bronchiolitis by assessment with modified TAL score (MTS)
7-day Same-Cause Revisit Rate	Discharge to 7 days	Measuring number of revisits to the primary care physician or emergency room or re-admission to the hospital for ongoing bronchiolitis related symptoms within 7 days of discharge

Countries

United States

Participant flow

Participants by arm

Arm	Count
Placebo Arm Participants will be given a placebo of sugar water (0.6ml/kg/dose) in a single oral dose and standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.) Placebos: Sugar water based on same ml dosing of intervention arm drug	2
Dexamethasone Arm Participants will be given dexamethasone (0.6mg/kg/dose) in a single oral dose in addition to the standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.) Dexamethasone Oral: 0.6mg/kg/dose - single oral dose administration to intervention arm	1
Total	3

Baseline characteristics

Characteristic	Placebo Arm	Dexamethasone Arm	Total
Age, Continuous	2.75 months STANDARD_DEVIATION 1.77	12 months	5.83 months STANDARD_DEVIATION 5.48
Race and Ethnicity Not Collected	—	—	0 Participants
Sex: Female, Male Female	1 Participants	0 Participants	1 Participants
Sex: Female, Male Male	1 Participants	1 Participants	2 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 2	0 / 1
other Total, other adverse events	0 / 2	0 / 1
serious Total, serious adverse events	0 / 2	0 / 1

Outcome results

Primary